|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12.18 CNY | -2.72% |
|
-3.03% | -31.96% |
| 27/05 | Zhejiang Jiuzhou Pharmaceutical plans share buyback | RE |
| 25/05 | Zhejiang Jiuzhou Pharmaceutical Co., Ltd authorizes a Buyback Plan. | CI |
Business description: Zhejiang Jiuzhou Pharmaceutical Co., Ltd
Number of employees: 4,791
Sales by Activity: Zhejiang Jiuzhou Pharmaceutical Co., Ltd
| Fiscal Period: December | 2021 (CNY) | 2022 (CNY) | 2023 (CNY) | 2024 (CNY) | 2025 (CNY) |
|---|---|---|---|---|---|
Patented APIs and Intermediates | 231.1Cr | 341.65Cr | 407.94Cr | 387.06Cr | 417.63Cr |
Specialty APIs (Active Pharmaceutical Ingredients) and Intermediates | 131.03Cr | 163.67Cr | 126.11Cr | 115.97Cr | 115.87Cr |
Others | 20Cr | 13Cr | 6.53Cr | 5.61Cr | 8.09Cr |
Geographical breakdown of sales: Zhejiang Jiuzhou Pharmaceutical Co., Ltd
| Fiscal Period: December | 2021 (CNY) | 2022 (CNY) | 2023 (CNY) | 2024 (CNY) | 2025 (CNY) |
|---|---|---|---|---|---|
Overseas | 293.14Cr | 415.4Cr | 430.67Cr | 402.46Cr | 423.24Cr |
China | 89Cr | 102.68Cr | 109.92Cr | 113.6Cr | 118.35Cr |
Executive Committee: Zhejiang Jiuzhou Pharmaceutical Co., Ltd
| Manager | Title | Age | Since |
|---|---|---|---|
Yi Jiang Mei
CEO | Chief Executive Officer | 51 | 28/03/2023 |
Yu Jie Sha
DFI | Director of Finance/CFO | 46 | 18/05/2021 |
Hui Lu Lin
SEC | Corporate Secretary | 53 | 18/11/2014 |
Bei Bei Wang
IRC | Investor Relations Contact | - | - |
Yuan Qiang Li
PRN | Corporate Officer/Principal | 60 | 06/06/2016 |
Composition of the Board of Directors: Zhejiang Jiuzhou Pharmaceutical Co., Ltd
| Director | Title | Age | Since |
|---|---|---|---|
Li Rong Hua
CHM | Chairman | 58 | - |
Xiao Hui Hua
BRD | Director/Board Member | 51 | 18/11/2014 |
Meng Sheng Sun
CHM | Chairman | 70 | 18/11/2014 |
Hui Lu Lin
BRD | Director/Board Member | 53 | 17/11/2020 |
Jin Kang Chen
BRD | Director/Board Member | 46 | 10/11/2020 |
Yu Jie Sha
BRD | Director/Board Member | 46 | 04/12/2023 |
Yi Jiang Mei
BRD | Director/Board Member | 51 | 06/09/2018 |
Biao Yu
BRD | Director/Board Member | 59 | 17/11/2020 |
Xing Qiu Wu
BRD | Director/Board Member | 42 | 17/11/2020 |
Qi Jiang
BRD | Director/Board Member | 46 | 07/08/2023 |
Company details: Zhejiang Jiuzhou Pharmaceutical Co., Ltd
Zhejiang Jiuzhou Pharmaceutical Co., Ltd.
99 Waisha Road
318000, Taizhou
+86 576 8558 8039
http://www.jiuzhoupharma.com
Other Pharmaceuticals
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.72% | -3.03% | -21.32% | -57.41% | 162.94Cr | |
| +2.28% | +3.43% | +43.93% | +161.35% | 1,01300Cr | |
| +0.48% | +5.13% | +54.50% | +50.01% | 57TCr | |
| +0.34% | +0.49% | +18.03% | +64.11% | 40TCr | |
| -0.37% | +4.97% | +21.24% | +15.95% | 32TCr | |
| +0.85% | +0.18% | +24.50% | +14.78% | 28TCr | |
| +2.10% | +4.92% | +25.30% | +33.80% | 27TCr | |
| +3.45% | +0.98% | +19.59% | +60.55% | 18TCr | |
| -0.19% | -0.46% | -45.32% | -48.35% | 19TCr | |
| +3.63% | -2.49% | +15.24% | +61.78% | 15TCr | |
| Average | +0.95% | +2.24% | +15.57% | +35.66% | 33.9TCr | |
| Weighted average by Cap. | +1.31% | +3.99% | +29.69% | +72.89% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Annual profits - Rate of surprise
- Stock Market
- Stocks
- 603456 Stock
- Company Zhejiang Jiuzhou Pharmaceutical Co., Ltd
Select your edition
All financial news and data tailored to specific country editions
